Double blind trial of clonidine in the treatment of migraine in a general practice.
The value of clonidine (;Dixarit') for the prophylaxis of migraine has been assessed by a double blind cross-over trial. A dose of up to 0.15 mg daily was used. No effect on the frequency of the headaches could be detected over and above the 60 per cent reduction observed with a placebo. Severity, assessed subjectively by the patient, when it varied between placebo and clonidine, was less with clonidine (p<0.01). There was also some evidence that headaches lasting more than 12 hours were less common during treatment with the drug.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002986:Clinical Trials as Topic; D003000:Clonidine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005194:Family Practice; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*
D003000:Clonidine